Blueprint Medicines Co. to Post Q1 2025 Earnings of ($0.93) Per Share, Wedbush Forecasts (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Analysts at Wedbush issued their Q1 2025 earnings estimates for Blueprint Medicines in a research report issued to clients and investors on Thursday, May 2nd. Wedbush analyst D. Nierengarten expects that the biotechnology company will earn ($0.93) per share for the quarter. Wedbush has a “Outperform” rating and a $110.00 price objective on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($5.38) per share. Wedbush also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.61) EPS and Q4 2025 earnings at ($0.43) EPS.

Other equities analysts have also recently issued reports about the company. Citigroup boosted their target price on Blueprint Medicines from $65.00 to $76.00 and gave the stock a “sell” rating in a research report on Friday. Stifel Nicolaus raised their price objective on Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, April 26th. SVB Leerink raised Blueprint Medicines from an “underperform” rating to a “market perform” rating and upped their price objective for the company from $50.00 to $97.00 in a research report on Monday. JMP Securities upped their price target on shares of Blueprint Medicines from $114.00 to $125.00 and gave the company a “market outperform” rating in a research report on Friday. Finally, Piper Sandler upped their price target on shares of Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a research report on Friday. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $100.31.

Blueprint Medicines Stock Down 0.9 %

BPMC opened at $106.25 on Monday. Blueprint Medicines has a 12 month low of $43.89 and a 12 month high of $110.93. The company has a market cap of $6.50 billion, a PE ratio of -22.14 and a beta of 0.65. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. The company has a 50 day moving average of $91.77 and a 200 day moving average of $80.95.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The firm had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. During the same quarter in the prior year, the company earned ($2.65) EPS. The business’s revenue for the quarter was up 85.5% on a year-over-year basis.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Christopher K. Murray sold 621 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $93.65, for a total transaction of $58,156.65. Following the transaction, the insider now directly owns 36,374 shares of the company’s stock, valued at $3,406,425.10. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider L. Becker Hewes sold 3,097 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total value of $280,866.93. Following the transaction, the insider now directly owns 46,281 shares of the company’s stock, valued at approximately $4,197,223.89. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Christopher K. Murray sold 621 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $93.65, for a total transaction of $58,156.65. Following the transaction, the insider now directly owns 36,374 shares of the company’s stock, valued at approximately $3,406,425.10. The disclosure for this sale can be found here. Insiders have sold 104,123 shares of company stock worth $9,554,679 over the last quarter. Insiders own 3.88% of the company’s stock.

Institutional Trading of Blueprint Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BPMC. Readystate Asset Management LP acquired a new position in Blueprint Medicines in the 4th quarter valued at $3,692,000. American Century Companies Inc. increased its stake in Blueprint Medicines by 5.2% during the third quarter. American Century Companies Inc. now owns 670,972 shares of the biotechnology company’s stock worth $33,696,000 after purchasing an additional 33,243 shares during the period. Diversified Trust Co raised its position in Blueprint Medicines by 2.9% in the 3rd quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock valued at $563,000 after purchasing an additional 318 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Blueprint Medicines by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock worth $78,000 after buying an additional 757 shares during the last quarter. Finally, Rafferty Asset Management LLC boosted its stake in Blueprint Medicines by 17.4% in the third quarter. Rafferty Asset Management LLC now owns 166,690 shares of the biotechnology company’s stock valued at $8,371,000 after acquiring an additional 24,693 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.